October 20, 2011 -- Simcere Pharma signed a strategic cooperation agreement with Suzhou NeuPharma to develop novel drugs. The first candidate is a cancer drug. Simcere will contribute its production and marketing expertise, while NeuPharma will be responsible for developing drug candidates. Simcere is a China biopharma that is expanding from its base of branded generic drugs by entering numerous innovative research collaborations. More details....
Stock Symbol: (NYSE: SCR)
